Hogan Lovells has advised EyePoint Pharmaceuticals, Inc. on the deal.
Cowen and Guggenheim Securities acted as joint book-running managers for the offering.
Among other uses, this capital raise sets the stage for EyePoint’s continued advancement of EYP-1901, its potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration, the leading cause of vision loss in people over 65.
The Hogan Lovells team was led by Philadelphia-based partner Steve Abrams (Picture) and counsel Stephen Nicolai. They were assisted by partners Susan Lee (Washington, D.C.) and Bob Underwood (Boston), counsel Teresa Lavenue (Washington, D.C), and associates Gibby Wagner (Philadelphia) and Sally Gu (Washington, D.C.).
Involved fees earner: Steve Abrams – Hogan Lovells; Sally Gu – Hogan Lovells; Teresa Lavenue – Hogan Lovells; Susan Lee – Hogan Lovells; Stephen Nicolai – Hogan Lovells; Robert Underwood – Hogan Lovells; Gibby Wagner – Hogan Lovells;
Law Firms: Hogan Lovells;
Clients: EyePoint Pharmaceuticals, Inc.;